Overview

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen-Cilag Pty Ltd

Treatments:

Esomeprazole
Rabeprazole